secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0000950170-23-018467
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome Q1 2023: Auvelity sales $15.7M, total revenue $94.6M, net loss narrows to $11.2M
--------------------------------------------------------------------------------

- Auvelity net product sales $15.7M in first full quarter; ~31,000 prescriptions, up 298% vs Q4 2022.
- Total Q1 revenue $94.6M including $65.7M upfront from Sunosi ex-U.S. license to Pharmanovia; net loss $(11.2)M ($0.26/sh) vs $(39.6)M ($1.03/sh) a year ago.
- Sunosi net sales $12.9M (U.S. $11.2M, int'l $1.7M); U.S. prescriptions up 13% YoY and 4% sequentially.
- Amended Hercules term loan to $350M with reduced rate, extended maturity; cash $246.5M at March 31.
- Pipeline milestones: AXS-12 Phase 3 narcolepsy topline Q2 2023; AXS-07 migraine NDA resubmission 2H 2023; AXS-14 fibromyalgia NDA submission Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017023018467/0000950170-23-018467-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017023018467/axsm-20230508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-018467

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer